MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Long-Term Debt 2011-2026 | BIO
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.2 B | 1.2 B | 1.2 B | 10.5 M | 1.8 M | 13.6 M | 439 M | 435 M | 434 M | 436 M | 436 M | 436 M | 732 M | 732 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.2 B | 1.8 M | 550 M |
Quarterly Long-Term Debt Bio-Rad Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | - | 1.2 B | 10.5 M | 10.6 M | 10.8 M | 10.9 M | 12.3 M | 12.2 M | 12.3 M | 12.3 M | 13.6 M | 438 M | 13.6 M | 13.6 M | 439 M | 439 M | 439 M | 439 M | 435 M | 435 M | 435 M | 435 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 733 M | 436 M | 732 M | 732 M | 732 M | 732 M | 732 M | 732 M | 732 M | 732 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.2 B | 10.5 M | 552 M |
Long-Term Debt of other stocks in the Medical devices industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
32.7 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Alphatec Holdings
ATEC
|
501 M | $ 13.94 | -0.71 % | $ 2.09 B | USA |
 |
Allied Healthcare Products
AHPI
|
2.93 K | - | 3.58 % | $ 2.21 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.01 M | $ 14.09 | -7.06 % | $ 381 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
71.3 M | - | - | $ 1.77 B | USA |
 |
Apollo Endosurgery
APEN
|
34 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
1.1 M | - | -20.74 % | $ 369 K | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
430 K | - | -5.86 % | $ 30.6 M | USA |
 |
AxoGen
AXGN
|
48.4 M | $ 31.87 | 2.07 % | $ 1.47 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
24.1 M | $ 7.0 | 5.74 % | $ 503 M |  Israel |
 |
EDAP TMS S.A.
EDAP
|
2.16 M | $ 4.38 | -4.58 % | $ 163 M |  France |
 |
Axonics Modulation Technologies
AXNX
|
7.56 M | - | - | $ 3.31 B | USA |
 |
Electromed
ELMD
|
1.1 M | $ 24.18 | 1.09 % | $ 204 M | USA |
 |
Aziyo Biologics
AZYO
|
20.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Apyx Medical Corporation
APYX
|
33.2 M | $ 3.49 | 2.05 % | $ 121 M | USA |
 |
Conformis
CFMS
|
20.6 M | - | - | $ 16.4 M | USA |
 |
BIOLASE
BIOL
|
11.8 M | - | -13.19 % | $ 166 K | USA |
 |
Bruker Corporation
BRKR
|
2.06 B | $ 40.88 | 2.48 % | $ 6.09 K | USA |
 |
BioSig Technologies
BSGM
|
103 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
11.1 B | $ 75.65 | 2.97 % | $ 112 B | USA |
 |
IRIDEX Corporation
IRIX
|
1.75 M | $ 1.47 | -2.0 % | $ 23.7 M | USA |
 |
IRadimed Corporation
IRMD
|
1.42 K | $ 102.4 | 1.89 % | $ 1.3 B | USA |
 |
CryoLife, Inc.
CRY
|
290 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
834 M | $ 45.89 | -0.18 % | $ 1.42 B | USA |
 |
Cardiovascular Systems
CSII
|
1.33 M | - | 0.15 % | $ 844 M | USA |
 |
LivaNova PLC
LIVN
|
345 M | $ 71.26 | 1.38 % | $ 3.89 B |  Britain |
 |
Itamar Medical Ltd.
ITMR
|
154 K | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
38.6 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
7.64 M | - | - | $ 111 M |  Canada |
 |
Cutera
CUTR
|
1.06 M | - | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
25.6 B | $ 97.22 | 0.58 % | $ 125 B | USA |
 |
Delcath Systems
DCTH
|
10.2 M | $ 9.11 | -10.77 % | $ 260 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
3.48 M | $ 2.48 | 1.02 % | $ 146 M | Israel |
 |
Intersect ENT, Inc.
XENT
|
63.6 M | - | - | $ 955 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.11 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
11.9 M | - | - | $ 10.2 M | USA |
 |
Second Sight Medical Products
EYES
|
18 M | - | -0.97 % | $ 54.4 M | USA |
 |
Establishment Labs Holdings
ESTA
|
220 M | $ 77.41 | -1.12 % | $ 2.18 B |  Costa-rica |
 |
Insulet Corporation
PODD
|
931 M | $ 251.74 | 1.46 % | $ 17.7 B | USA |
 |
Quanterix Corporation
QTRX
|
37.2 M | $ 6.7 | 6.52 % | $ 252 M | USA |
 |
GBS
GBS
|
1.65 M | - | -0.57 % | $ 7.12 M | USA |
 |
FONAR Corporation
FONR
|
155 K | $ 18.53 | -0.3 % | $ 121 M | USA |
 |
Sintx Technologies
SINT
|
3.69 M | $ 2.89 | -1.87 % | $ 10.8 M | USA |
 |
MiMedx Group
MDXG
|
16.5 M | $ 4.97 | -5.78 % | $ 735 M | USA |